KPTI News and Press, Karyopharm Therapeutics Inc. From 11/16/20

Xpovio is showing good uptake after about a year on the market. The second line multiple myeloma indication will likely be added next Spring. Karyopharm looks substantially undervalued even without factoring in any of the pipeline beyond Xpovio’s first three indications. ...

Recent advancements in readouts for Xpovio and Selinexor have yet to be reflected in market pricing, in our view. Karyopharm has had an in line quarter, where Xpovio sales were driven by new prescriber accounts and upward trends in average refill rate. Based on the commercial pote...

Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet PR Newswire NEWTON, Mass., Nov. 12, 2020 NEWTON, Mass. , Nov. 12, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage ...

Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference PR Newswire NEWTON, Mass., Nov. 10, 2020 NEWTON, Mass. , Nov. 10, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company ...

Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting -- Updated Results from the Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating XPOVIO in Combination...

Image source: The Motley Fool. Karyopharm Therapeutics Inc (NASDAQ: KPTI) Q3 2020 Earnings Call Nov 2, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics Inc (KPTI) Q3 2020 Earnings Call Transcr...

Karyopharm Therapeutics, Inc. (KPTI) Q3 2020 Earnings Conference Call November 2, 2020 4:30 p.m. ET Company Participants Ian Karp - VP, Investor and Public Relations Michael Kauffman - CEO Sharon Shacham - President and Chief Scientific Officer Mike Mason - CFO John Demaree - Chief Commercial...

Karyopharm Therapeutics, Inc. (KPTI) Q3 2020 Earnings Conference Call October 2, 2020 16:20 AM ET Company Participants Ian Karp - VP, Investor & Public Relations Michael Kauffman - Co-Founder, CEO & Director John Demaree - Chief Commercial Officer Michael Mason - SVP, CFO & Treasu...

Karyopharm Therapeutics (KPTI) announces positive results from a Phase 3 clinical trial, SEAL, evaluating Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, a high-grade subtype of the rare form of soft tissue cancer that begins in fat cells.The study met ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation